3 active not recruiting, 1 terminated. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 3, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow venglustat: new trials by email Literature Review of venglustat trials Research Report on venglustat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828) - Fabry Disease | Phase 3 | Active not recruiting | Sanofi | 104 | 2022-05-03 | 2026-06-24 |
| Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 Venglustat, imiglucerase - Gaucher's Disease Type III | Phase 3 | Active not recruiting | Sanofi | 43 | 2022-04-18 | 2026-07-13 |
| A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Venglustat (GZ402671), Placebo - Fabry Disease | Phase 3 | Active not recruiting | Sanofi | 122 | 2022-03-11 | 2026-10-13 |
| A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients Venglustat, Placebo - Polycystic Kidney, Autosomal Dominant | Phase 2 / Phase 3 | Terminated | Genzyme, a Sanofi Company | 478 | 2018-10-04 | 2023-02-03 |
Fabry Disease (2) · Gaucher Disease (1) · Polycystic Kidney, Autosomal Dominant (1)
Sanofi (3) · Genzyme, a Sanofi Company (1)
Canada (4) · China (4) · France (4) · Germany (4) · Italy (4) · Japan (4) · Turkey (Türkiye) (4) · United Kingdom (4) · United States (4) · Argentina (3) · Austria (3) · Denmark (3) · Poland (3) · Australia (2) · Czechia (2)
PMID 36204243, PMID 36535535, PMID 39356039
2017 (1), 2023 (1)